Warren-based Aquestive Therapeutics Inc. has named Santo “Sandy” Costa as chairman of its Board of Directors.
Costa has served as a member of the board since 2015. He took over the chairman position effective Aug. 8, replacing Douglas Bratton, who had served in the role since 2004. Bratton remains as a member of the board.
“Aquestive is uniquely positioned with a broad pipeline that spans late stage CNS candidates and earlier stage orally administered complex molecules. I look forward to continuing to work with the board and the executive team as Aquestive transitions to a commercial organization in the coming months,” Costa said in a release.
Costa has 40 years of experience in the pharmaceutical, health, life sciences and legal industries. He also sits on the boards of Cytokinetics Inc. and Metabolon Inc. and is of counsel at Smith, Anderson, Blount, Doresett, Mitchell and Jernigan law firm in Raleigh, N.C.